Third Quarter Earnings Briefs: Lilly, Bristol, Shire, Biomarin, Alexion
Executive Summary
Lilly lowers expectations for Cymbalta; Celgene’s Abraxane continues with strong sales; Bristol touts the potential of Eliquis and Bydureon, despite slow sales; Ornskov discusses One Shire plan; BioMarin readies fifth compound for the clinic, and more.
You may also be interested in...
Cardio And Metabolic Deals, Launches Falter – Will Innovation Help?
Despite the high unmet medical need in the cardiovascular and metabolic indications, companies are increasingly reluctant to make deals in the sector. But unique therapeutic approaches to diseases could bring new life.
Sangamo Adds To Its Own Gene Therapy Technology With Ceregene Buy
The biotech will bolster its own internal programs, as well as gain a potentially lucrative mid-stage asset through the acquisition, with no effect on its own balance sheet.
Facing Manufacturing Woes, Alexion Strengthens Leadership
Martin Mackay, who left AstraZeneca at the end of January after new CEO Pasqual Soriot eliminated his position as head of global R&D, is joining Alexion’s senior management team, even as the highly successful, rare disease-focused biotech seeks to put manufacturing woes behind it.